249 related articles for article (PubMed ID: 5527170)
21. Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. A hypothesis on their mode of interaction with the central dopamine receptor.
Humber LG; Bruderlein FT; Voith K
Mol Pharmacol; 1975 Nov; 11(6):833-40. PubMed ID: 1239657
[No Abstract] [Full Text] [Related]
22. Effect of dopaminergic agonists and antagonists on in vivo cyclic nucleotide content: relation of guanosine 3':5'- monophosphate (cGMP) changes in cerebellum to behavior.
Breese GR; Mueller RA; Mailman RB
J Pharmacol Exp Ther; 1979 May; 209(2):262-70. PubMed ID: 35602
[No Abstract] [Full Text] [Related]
23. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
24. The interaction of neuroleptic and muscarinic agents with central dopaminergic systems.
Kelly PH; Miller RJ
Br J Pharmacol; 1975 May; 54(1):115-21. PubMed ID: 1139072
[TBL] [Abstract][Full Text] [Related]
25. The effect of butaclamol and of other neuroleptic agents on the apomorphine-elicited inhibition of synaptosomal tyrosine hydroxylase activity.
Bronaugh RL; Tabak J; Ohashi T; Goldstein M
Psychopharmacol Commun; 1975; 1(5):501-10. PubMed ID: 7003
[TBL] [Abstract][Full Text] [Related]
26. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats.
Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM
Arzneimittelforschung; 1967 Jul; 17(7):841-54. PubMed ID: 5632842
[No Abstract] [Full Text] [Related]
27. The neuroleptics. 5. Animal behavior.
Buser P; Cook L; Giurgea C; Jacobsen E; Ray OS; Richelle M; Silverman AP; Stein L; Votava Z
Mod Probl Pharmacopsychiatry; 1970; 5():85-108. PubMed ID: 5005610
[No Abstract] [Full Text] [Related]
28. Chemical and pharmacological classification of neuroleptics.
Janssen PA
Mod Probl Pharmacopsychiatry; 1970; 5():33-44. PubMed ID: 5535847
[No Abstract] [Full Text] [Related]
29. Definition and classification of neuroleptics.
Arnold OH; Collard J; Deniker P; Ginestet D; Hippius H; Itil TM; Labhardt F; Leeds AA; Montanini R; Morozov G; Simon P; Villeneuve A
Mod Probl Pharmacopsychiatry; 1970; 5():141-7. PubMed ID: 5527163
[No Abstract] [Full Text] [Related]
30. [Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].
Pavón N; Vidal L; Alvarez P; Blanco L; Torres A; Rodríguez A; Macías R
Rev Neurol; 1998 Jun; 26(154):915-8. PubMed ID: 9658459
[TBL] [Abstract][Full Text] [Related]
31. Molindone hydrochloride: a review of laboratory and clinical findings.
Owen RR; Cole JO
J Clin Psychopharmacol; 1989 Aug; 9(4):268-76. PubMed ID: 2671060
[TBL] [Abstract][Full Text] [Related]
32. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine.
Moroz IA; Peciña S; Schallert T; Stewart J
Exp Neurol; 2004 Sep; 189(1):78-93. PubMed ID: 15296838
[TBL] [Abstract][Full Text] [Related]
33. Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens.
Robbins TW; Roberts DC; Koob GF
J Pharmacol Exp Ther; 1983 Mar; 224(3):662-73. PubMed ID: 6402587
[TBL] [Abstract][Full Text] [Related]
34. The neuroleptics. 2. Neurophysiology and neuropharmacology.
Albe-Fessard D; Bradley PB; Gerschenfeld HM; Herz A; Krnjević K; Lodin Z; Marczynski TJ; Massion J; Meulders M; Poirier LJ; Salmoiraghi GC; Schlag J; Tauc L; Wall PD
Mod Probl Pharmacopsychiatry; 1970; 5():12-22. PubMed ID: 4348144
[No Abstract] [Full Text] [Related]
35. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fuxe K; Werge T; Gerlach J
Behav Pharmacol; 2002 Dec; 13(8):639-44. PubMed ID: 12478214
[TBL] [Abstract][Full Text] [Related]
36. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.
Burt DR; Creese I; Snyder SH
Science; 1977 Apr; 196(4287):326-8. PubMed ID: 847477
[TBL] [Abstract][Full Text] [Related]
37. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
Koltai MZ; György L
Acta Physiol Acad Sci Hung; 1981; 58(3):225-33. PubMed ID: 7348023
[TBL] [Abstract][Full Text] [Related]
38. Proceedings: Interaction of neuroleptic and cholinergic drugs with central dopaminergic mechanisms.
Kelly P; Miller RJ; Sahakian B
Br J Pharmacol; 1974 Nov; 52(3):430P-431P. PubMed ID: 4477511
[No Abstract] [Full Text] [Related]
39. [Effect of neuroleptic agents in the chronic pharmacological experiment].
Stille G; Lauener H
Arzneimittelforschung; 1974 Sep; 24(9):1292-4. PubMed ID: 4479794
[No Abstract] [Full Text] [Related]
40. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
